Joseph Murray, M. D., discusses a recently published article in the Indian Journal of Medical Research about bone diseases, a common complication of celiac disease.
This study examined a small trial group of celiac disease patients that received two different standard therapies. One therapy was a gluten-free diet and a calcium D supplement. The second therapy was zoledronic acid, a bisphosphonate. The results show there is vast improvement in bone density in both groups within a twelve month follow up. The zoledronic acid improvement was not significantly different than the standard treatment in terms of improvement.
Bone disease is common and needs to be actively managed. A gluten-free along with supplements of vitamin D and calcium is the first line of treatment for bone disease. More aggressive or bone specific therapies are best reserved for secondary use.
Read the full study online here.
For more information on celiac disease, visit mayoclinic.org/celiacdisease.
Dr. Murray is a gastroenterologist and celiac disease expert at Mayo Clinic.